Showing results (1841-1850 of 1,970) with videos related to

Sort By:
Pageof 197
Clinical Genitourinary Cancer|December 1, 2021
Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the NetherlandsMalou C P Kuppen, Hans M Westgeest, Alfons J M van den Eertwegh, et al.
Journal of Affective Disorders|July 17, 2025
Do young people get the mental healthcare they need? Trajectories of depressive symptoms, correlates and care pathways in a clinical sample of young people reaching the upper age limit of their CAMHSLarissa S van Bodegom, Suzanne E Gerritsen, Athanasios Maras, et al.
Breast (Edinburgh, Scotland)|November 28, 2025
Outcomes for ER-positive CHEK2 c.1100delC breast cancer patients compared with breast cancer patients without the variantMaartje A C Schreurs, Muriel A Adank, Bernadette A M Heemskerk-Gerritsen, et al.
Schizophrenia Bulletin|August 8, 2024
The Association Between Trajectories of Self-reported Psychotic Experiences and Continuity of Mental Health Care in a Longitudinal Cohort of Adolescents and Young AdultsSuzanne E Gerritsen, Koen Bolhuis, Larissa S van Bodegom, et al.
European Journal of Human Genetics : EJHG|January 5, 2006
A genome-wide search for linkage to asthma phenotypes in the genetics of asthma international network families: evidence for a major susceptibility locus on chromosome 2pSreekumar G Pillai, Mathias N Chiano, Nicola J White, et al.
European Urology|August 20, 2020
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term SurvivorsKarim Fizazi, Charles G Drake, Tomasz M Beer, et al.
Prostate Cancer and Prostatic Diseases|July 13, 2021
Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancerBastiaan M Privé, Peter H J Slootbeek, Babette I Laarhuis, et al.
Journal of the National Cancer Institute|March 20, 2015
Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reductionB A M Heemskerk-Gerritsen, C Seynaeve, C J van Asperen, et al.
Breast (Edinburgh, Scotland)|December 20, 2021
Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort studyDelal Akdeniz, Mark van Barele, Bernadette A M Heemskerk-Gerritsen, et al.
Clinical Genitourinary Cancer|March 13, 2025
Learning From Evidence: Changes in Real-World Use of Second Androgen Receptor Targeted Treatments in Metastatic Castration-Resistant Prostate Cancer (mCRPC)Dianne Bosch, Kim J M van der Velden, Tom Belleman, et al.
Pageof 197